MEDTECHS DEFLATE FURTHER
13/03/25 -"It has been some time since AlphaValue last bashed MedTechs, its recurring bête noire when it comes to lofty valuations. In fairness the sector has taken care of itself of late. Five years after ..."
Pages
64
Language
English
Published on
13/03/25
You may also be interested by these reports :
29/07/26
bioMerieux’s H1 profitability largely met expectations. Q2 sales growth was driven by increases across both segments, supported by its GO28 growth ...
28/07/26
Philips’ Q2 sales surpassed expectations, with profitability excluding one-offs meeting forecasts. The 2026 guidance was reaffirmed. However, ...
24/07/26
Sartorius reported mixed Q2 26 numbers, with revenue below consensus (-2.3%) but underlying EBITDA slightly ahead (+0.5%). Equipment inflected as ...
23/07/26
Sartorius Stedim Biotech reported mixed Q2 26 numbers, with revenue below consensus (-2.8%) but underlying EBITDA ahead (+1.1%). The miss is largely ...